Emily's practice encompasses a broad range of corporate and transactional matters for public and private companies, with a particular focus on debt financings and corporate governance.
She advises clients on a variety of corporate debt finance transactions, including working capital facilities, investment fund credit facilities, syndicated facilities, and portfolio leverage facilities. Throughout all stages of the financing process, Emily provides practical guidance to both borrowers and lenders, including public companies, emerging growth companies, private equity sponsors, private funds and direct lenders.
In addition to debt finance, Emily counsels public and private companies on a wide array of transactional matters, such as company formation and structuring, venture capital financings, mergers and acquisitions, and general corporate governance. She also advises public companies on public and private offerings of equity, SEC reporting obligations, and compliance with ongoing annual and periodic reporting requirements, including Section 16 matters and annual and special stockholder meetings.
University of Michigan – Stephen M. Ross School of Business, M.M., 2019
University of Michigan, B.A., 2018
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
Experience
AstroNova, Inc. (Nasdaq: ALOT), a leading provider of mission critical identification and marking solutions across the aerospace & defense and labeling & packaging industries, in its acquisition by Arcline Investment Management, a growth-oriented private equity firm for $272 million
Pacific General in connection with a strategic investment in Old World Provisions, Inc. and the formation of a consortium with S Food Inc., a leading South Korean food manufacturer focused on value-added meat products and high-quality food ingredients
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA), a clinical-stage biotechnology company, on its $74.8 million public offering, which included the underwriters’ full exercise of their option to purchase additional shares
Organogenesis Holdings, a regenerative medicine company, in its $130 million PIPE of Series A Convertible Preferred Stock
Modern Hydrogen (formerly Modern Electron), a sustainable heat and hydrogen company, in an oversubscribed $32.8 million Series B-2 funding round
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, in its acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
